Search

Search Constraints

You searched for: Author/Creator Haanen, John B. A. G.

Search Results

1. A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma. (4th March 2019)

3. Antigen‐specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy. Issue 6 (3rd May 2016)

4. Discontinuation of anti‐PD‐1 monotherapy in advanced melanoma—Outcomes of daily clinical practice. Issue 2 (2nd October 2021)

5. Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). (November 2013)

6. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Issue 2 (10th January 2022)

7. Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial. Issue 2 (August 2021)

8. Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial. Issue 2 (9th August 2021)

9. Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile. (2nd November 2019)

10. Real‐world outcomes of advanced melanoma patients not represented in phase III trials. Issue 12 (4th July 2020)